Groundbreaking Cancer Drug Trial by GSK Yields Impressive Results
GSK's new cancer treatment, Mo-Rez, shows remarkable tumor reduction in over 60% of patients with ovarian and endometrial cancers, setting the stage for a potential blockbuster drug.
GSK, the renowned pharmaceutical company, has announced promising early results from a clinical trial of its new cancer drug, Mocertatug Rezetecan (Mo-Rez). The treatment has demonstrated remarkable success in reducing or eliminating tumors in patients with ovarian and endometrial cancers, where traditional chemotherapy had failed.
According to the company's findings, Mo-Rez shrank or eliminated tumors in 62% of patients with ovarian cancer and 67% of those with endometrial cancer. These results are particularly significant, as GSK's chief executive, Luke Miels, has been leading the charge to bolster the company's drug development efforts.
Source: The Guardian
